MARKET

TRAW

TRAW

Traws Pharma
NASDAQ
0.6044
-0.0163
-2.62%
Pre Market: 0.6335 +0.0291 +4.81% 08:33 05/29 EDT
OPEN
0.6200
PREV CLOSE
0.6207
HIGH
0.6370
LOW
0.6024
VOLUME
50
TURNOVER
0
52 WEEK HIGH
1.330
52 WEEK LOW
0.5509
MARKET CAP
15.29M
P/E (TTM)
-0.6995
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TRAW last week (0520-0524)?
Weekly Report · 2d ago
Weekly Report: what happened at TRAW last week (0513-0517)?
Weekly Report · 05/20 09:54
Traws Pharma’s High-Stakes Merger: The Race Against Time for Financial Success
TipRanks · 05/17 06:00
Onconova Therapeutics GAAP EPS of -$0.24 beats by $0.01, revenue of $0.06M in-line
Seeking Alpha · 05/16 17:07
Traws Pharma Q1 EPS $(0.24) Up From $(0.28) YoY, Sales $56.00K, Same YoY
Benzinga · 05/16 13:31
TRAWS PHARMA - BELIEVES THAT CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ONGOING CLINICAL TRIALS AND BUSINESS OPERATIONS INTO Q4 OF 2024
Reuters · 05/16 13:29
Press Release: Traws Pharma Reports First Quarter -2-
The company's stockholders' equity is based on the value of the company's common stock. The company has a market value of more than $1 billion. It has a long-term goal of raising its stock value to $10 billion. The stock is expected to reach $20 billion by the end of the year.
Dow Jones · 05/16 13:29
*Traws Pharma 1Q Loss/Shr 24c >TRAW
Dow Jones · 05/16 13:29
More
About TRAW
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).

Webull offers Traws Pharma Inc stock information, including NASDAQ: TRAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRAW stock methods without spending real money on the virtual paper trading platform.